Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Larger AUM within category. | ||
Cons | - | - |
INDMoney rank | 3/8 | 2/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 9 Years | 6 Years | ||
Fund Size | 1232 Cr | 5508 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.63% | 1.06% | ||
Exit Load | 0.25% | 1% | ||
Benchmark Index | Nifty Pharma TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.64%) Apollo Hospitals Enterprise Ltd (6.22%) Cipla Ltd (5.83%) Aurobindo Pharma Ltd (5.73%) Divi's Laboratories Ltd (5.63%) | Sun Pharmaceuticals Industries Ltd (12.66%) Dr Reddy's Laboratories Ltd (9.66%) Divi's Laboratories Ltd (9.03%) Cipla Ltd (7.85%) Aurobindo Pharma Ltd (6.34%) | ||
No of Sectors | 2 | 3 | ||
Top 3 Sectors | Health (97.4%) Basic Materials (2.6%) | Health (94.88%) Basic Materials (3.81%) Financial Services (1.31%) | ||
Equity % | 90.84% | 96.99% | ||
Debt % | - | - | ||
P/E | 35.88 | 30.46 | ||
P/B | 5.3 | 4.13 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 1.77% | 1.49% | ||
3-Month Return | 5.32% | 7.77% | ||
6-Month Return | -3.79% | 0.05% | ||
1-Year Return | 16.82% | 23.69% | ||
3-Year Return | 26.45% | 30.57% | ||
5-Year Return | 23.24% | 25.42% |
Sharpe | 1.04 | 1.3 | ||
Alpha | 4.08 | 4.24 | ||
Beta | 0.95 | 0.95 | ||
Standard Deviation | 16.18 | 15.67 | ||
Information Ratio | 1.33 | 1.44 |
Description | Tata India Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Meeta Shetty | Dharmesh Kakkad |